Pharmaceutical Supply – Ciprofloxacin Hydrochloride and Dexamethasone

The contract entails the manufacture and supply of a sterile ophthalmic solution containing ciprofloxacin hydrochloride and dexamethasone, formulated to meet stringent quality standards set by the FDA, the Department of Defense, and current Good Manufacturing Practices. The product is intended for delivery to a U.S. Navy vessel, ensuring military personnel have access to a therapeutically validated ophthalmic treatment compliant with federal and defense-level pharmaceutical regulations. Manufacturing must consistently adhere to cGMP protocols to guarantee sterility, potency, and safety, with all processes subject to regulatory oversight to maintain compliance in a high-stakes operational environment. The contract falls under NAICS code 325412, which categorizes it within pharmaceutical and medicinal product manufacturing, and is issued under the Defense Logistics Agency, reflecting its role within the broader DoD supply chain infrastructure. Final delivery is directed to a U.S. Navy vessel, underscoring the mission-critical nature of the product in supporting the health and readiness of deployed naval forces.